According to the guidelines of the National Comprehensive Cancer Network, molecular tests of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), B-Raf Proto-Oncogene (BRAF), mesenchymal-epithelial transition (MET), and rearranged during transfection (RET) are recommended for all non-small cell lung cancers (NSCLC) if specimens are sufficient for molecular analysis (1). This evidence concerns the gene ALK and non-small cell lung carcinoma.